Incyte Corp
(NAS:INCY)
$
69.91
0.07 (0.1%)
Market Cap: 13.47 Bil
Enterprise Value: 11.73 Bil
PE Ratio: 499.36
PB Ratio: 4.25
GF Score: 89/100 Incyte Corp at RBC Global Healthcare Conference Transcript
May 19, 2020 / 07:05PM GMT
Release Date Price:
$94.92
(-1.60%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good afternoon, everyone. I'm Brian Abrahams, one of the Senior Biotech Analysts here at RBC Capital Markets. It's my pleasure to introduce our next company, Incyte. Representing Incyte will be their Chairman, President and CEO; Hervé Hoppenot; as well as their Executive Vice President and CFO, Christiana Stamoulis. Hervé and Christiana, thanks so much for joining us today.
HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO
© -
Thank you. Good afternoon.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Great. So why don't we hop right in? Let's start with Jakafi. It seems like there's been relatively limited impact to the commercial business from the pandemic. And I was wondering if you could maybe talk a little bit about how the dynamics between the MF and PV markets, in particular, have evolved since the pandemic began
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot